Merck is Very Much a No Go - Avis employé Data Research Scientist Merck

1,0
28 févr. 2016
Recommande
Approbation du PDG
Perspective commerciale

Avantages

A few good people remain. Company benefits are average or above, other than tuition reimbursement which now is inadequate to earn a MS.

Inconvénients

Very much a dying company. Astonishingly bad esprit de corps, much worse now than when I joined over a decade ago. In the past 3 years, 90% of R&D talent has left the company or transferred to other divisions. Upper management are trying to convert all the remaining R&D and IT tasks into mechanized processes to then outsource them (supposedly saving money). All corporate initiative focuses either on saving money or on promoting Keytruda.

Découvrez plus d’avis sur Merck

5,0
3 juin 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

End of the year shutdown which includes paid time off

Inconvénients

The con for me at the time was that I had to relocate which wasn’t possible

4,0
2 juin 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Over my tenure, I had the opportunity to work alongside highly talented and mission-driven colleagues dedicated to improving patient outcomes. The organization provided exposure to cross-functional collaboration, leadership development opportunities, and meaningful work supporting healthcare providers, patients, and community stakeholders. I appreciated the company's commitment to innovation, professional growth, and serving patients through scientific advancement.

Inconvénients

Like many large organizations, priorities and organizational structures evolved over time, which occasionally created uncertainty and changes in responsibilities. Decision-making processes could sometimes be complex due to the size of the organization, and navigating multiple layers of stakeholders occasionally impacted speed and execution.

Voir les avis par: Utile|Évaluation|Date|Tout